Apogee Therapeutics
The Director, Cell Culture Development will lead TechOps activities to advance protein-based biologics through clinical development and toward commercialization. This role manages relationships with CDMOs and provides technical leadership for scale-up, tech transfer, and late-phase manufacturing campaigns. The position is embedded in the Drug Substance Development and Manufacturing organization and collaborates closely with analytical, device, drug product, and supply chain teams to support regulatory submissions and product launch readiness.
Headquarters
San Francisco, California, United States
Company Size
51-200 employees
Founded
2022
Apogee Therapeutics is a clinical-stage biotechnology company developing differentiated biologics for immunological and inflammatory diseases. The company focuses on high-unmet-need conditions including atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other I&I disorders. Apogee advances therapeutic candidates through clinical development with the goal of delivering best‑in‑class treatments for patients with inflammatory and immune-mediated diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Apogee Therapeutics.
A Look At Apogee Therapeutics (APGE) Valuation After Wider Losses And A New Shelf Registration
2 days ago
Director / Principal Scientist, Biologics Drug Substance Commercialization (BDSC)
MSD
Associate Principal Scientist, Engineering- Cell Culture Development & Commercialization
MSD
Process Development Senior Scientist
Amgen
Senior Scientist, Bioprocess Drug Substance Commercialization-3
MSD
Principal Scientist/Director
Merck & Co., Inc.
Principal Scientist/Director
Merck & Co., Inc.